Biondvax’s Universal Flu Vaccine Receives Additional US Patent

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled “Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines” has completed examination and is allowed for issuance as a patent.

The invention covers the use of BiondVax’s universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax’s completed clinical trials have shown significantly increased effectiveness against multiple flu strains.

Ron Babecoff, CEO of BiondVax commented, “Current flu vaccines are strain specific and are not particularly effective against circulating ‘wild-type’ strains due to mismatches. In fact, last year’s seasonal flu vaccine was only 23% effective^[1]. Conversely, our vaccine provides long-lasting and higher effectiveness against multiple flu strains.”

Continued Dr. Babecoff, “Our newly approved US patent demonstrates the novel nature of our vaccine technology and strengthens our IP portfolio for many years to come.”

Contego Medical Presents Data For Paladin® Carotid Post-Dilation Balloon

Contego Medical, an innovator in developing next generation treatments for coronary and peripheral artery disease, today presented positive post-market registry data for the Paladin® Carotid Post-Dilation Balloon with Integrated Embolic Protection™ (IEP) Technology at LINC 2016, in Leipzig, Germany. The presentation included compelling results from a diffusion-weighted MRI (DW-MRI) sub-study that showed improved patient outcomes with the Paladin System.

Dr. Ravish Sachar, CEO and Founder of Contego Medical, presented the preliminary results on symptomatic and asymptomatic carotid stenosis patients for 50 post-market registry patients and 15 DW-MRI sub-study patients. The post-market registry demonstrated a 100 percent success rate for delivery and deployment of the Paladin System, without the occurrence of device related complications over a 30-day follow-up period.  Exhibiting excellent outcomes, the DW-MRI sub-study results compare favorably to published results for carotid stenting with single distal protection or proximal protection.

“These preliminary results are consistent with previous findings and validate the Paladin System as a new meaningful technology in the carotid market,” stated Dr. Ralf Langhoff, Director of Angiology, Saint Getrauden Hospital, Berlin, Germany. “My experience in the post-market registry has been very positive. By incorporating this system into my practice, I can post-dilate the carotid stent and capture smaller embolic debris in a single step.”

The Paladin System provides vital embolic protection during the critical post-dilation step of a carotid stent procedure. By integrating a low-profile balloon and a 40-micron embolic filter into one catheter, the system simplifies the procedure and may improve safety.

“The positive results strengthen our belief in the Paladin System and the promise it holds to reduce the incidence of stroke in patients undergoing a carotid stenting procedure,” commented Dr. Sachar. “Emboldened by the enthusiasm that continues to grow in the European clinical community, we are committed to ongoing clinical research to rigorously study this novel platform.”